Sep 14, 2026 · 1h 59m
Early LDL lowering may protect the heart and brain
#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.
The discussion connects lifelong cholesterol exposure to cardiovascular disease and examines whether earlier lipid treatment could also prevent Alzheimer’s disease.
- 1Cumulative LDL exposure drives cardiovascular risk, making prevention decades before symptoms more consequential than short-term risk scores suggest.
- 2Obicetrapib could expand lipid-lowering options, but its cardiovascular role depends on the ongoing PREVAIL outcomes trial.
- 3CETP inhibition may offer an Alzheimer’s prevention strategy for APOE4 carriers, though biomarker evidence remains preliminary and unproven clinically.
Don't miss
Davidson explains why APOE4 carriers may need to consider Alzheimer’s prevention decades before dementia, while acknowledging that the evidence is not yet definitive.
The brief
Cardiologist and lipidologist Michael Davidson argues that LDL risk accumulates over a lifetime, while clinical practice often waits until short-term risk becomes visible.
The history of CETP inhibitors shows why biology alone is not enough: torcetrapib failed through off-target harm, while later evidence strengthened the case for LDL lowering.
Davidson’s obicetrapib program aims to combine potent LDL, ApoB, LDL-particle, and Lp(a) reduction with tolerability; the PREVAIL trial will determine its cardiovascular value.
The conversation then moves from arteries to the brain, exploring whether CETP inhibition could help APOE4 carriers decades before Alzheimer’s symptoms appear.
Biomarkers such as p-tau217, omega-3 formulations, AI-enabled trials, statin tradeoffs, and therapies such as Clotho all point to promise without settled clinical proof.
Books & mentions
Some links are affiliate links — PodLume may earn a commission if you buy.
